Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (203 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 14 | 980 | 44% |
| 2020 | 18 | 987 | 46% |
| 2021 | 17 | 1,016 |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 84% of the cases CMS names in Arizona; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 71 | 3,581+0.9%/yr | +0.9%/yr | 1.2 | 0% | 4,490 in 2030+3.9%/yr |
| Washington | 17 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 79 | 6,117−8.2%/yr | −8.2%/yr | 8.21.9× | 55% | 6,220 in 2030+0.3%/yr |
| Kidney stone management |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
| 2024 |
| 942 |
| 54% |
| 2025 est. | ≈ 1,070 | – |
| 2026 est. | ≈ 1,100 | – |
| 49% |
| 2022 | 14 | 886 | 51% |
| 2023 | 17 | 956 | 53% |
| 2024 | 14 | 942 | 54% |
| 2025 from claims | – | 1,067 863–1,253 | 55% |
| 2026 forecast | – | 1,096 859–1,377 | 55% |
| 2027 forecast | – | 1,121 831–1,482 | 56% |
| 2028 forecast | – | 1,146 811–1,582 | 56% |
| 2029 forecast | – | 1,172 796–1,680 | 57% |
| 2030 forecast | – | 1,198 785–1,778 | 57% |
In 2025, 32% inpatient hospital, 68% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~1,100 | ~330 | ~760 |
| 2027 · ~1,100 | ~330 | ~790 |
| 2028 · ~1,100 | ~340 | ~810 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 30% (32% in 2025), hospital outpatient about 70% (68% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 909−2.1%/yr |
| −2.1%/yr |
| 1.3 |
| 0% |
| 790 in 2030−2.3%/yr |
| Colorado | 9 | 636−1.1%/yr | −1.1%/yr | 1.4 | 0% | 690 in 2030+1.4%/yr |
| Oregon | 10 | 568−2.4%/yr | −2.4%/yr | 1.5 | 0% | 610 in 2030+1.2%/yr |
| Utah | 3 | 285+1.5%/yr | +1.5%/yr | 1.4 | 0% | 440 in 2030+7.5%/yr |
| Idaho | 5 | 276+4.7%/yr | +4.7%/yr | 1.5 | 0% | 260 in 2030−1.1%/yr |
| Montana | 6 | 237−1%/yr | −1%/yr | 1.3 | 0% | 280 in 2030+2.8%/yr |
| Nevada | 4 | 227−1.5%/yr | −1.5%/yr | 0.9 | 0% | 510 in 2030+14%/yr |
| 76 |
| 3,933−3.7%/yr |
| −3.7%/yr |
| 5.41.6× |
| 10% |
| 4,060 in 2030+0.5%/yr |
| Incontinence, prolapse & sacral neuromodulation | 38 | 2,602+2%/yr | +2%/yr | 3.52.1× | 38% | 2,760 in 2030+1%/yr |
| Hysterectomy, hysteroscopy & ablation | 21 | 1,973+0.3%/yr | +0.3%/yr | 2.91.3× | 22% | 2,360 in 2030+3%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Intuitive Surgical leads with 100% of company spending on these surgeons in 2025, level with 2024.
In 2025, 2 companies reported engagement with Arizona’s surgeons worth $200K in consulting, speaking, meals and travel tied to these products, about $14K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.